You are here

Preventing asthma exacerbations by reducing viral respiratory infections

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43HL115903-01
Agency Tracking Number: R43HL115903
Amount: $301,296.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NHLBI
Solicitation Number: PA11-096
Timeline
Solicitation Year: 2012
Award Year: 2012
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
3900 Essex Lane #250
Houston, TX 77027-
United States
DUNS: 786704143
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 BRENTON SCOTT
 (713) 563-0425
 bscott@pulmotect.com
Business Contact
 BRENTON SCOTT
Phone: (713) 579-9226
Email: bscott@pulmotect.com
Research Institution
 Stub
Abstract

DESCRIPTION (provided by applicant): Asthma is a leading cause of respiratory disease worldwide, with an estimated 300 million people affected and up to 250,000 deaths per year. Even in developed countries, asthma continues to be a burden for nearly 10% ofthe population with substantial time lost from work and school and considerable health care expenditures. The principal cause of asthma exacerbations is viral respiratory infections, estimated to be responsible for more than 70%. Pulmotect's Solution: Pulmotect has identified and is developing a novel technology to prevent respiratory infections. The lead drug (PUL-042) is a combination of two TLR ligands that stimulates the lung's own innate defense mechanisms to create a hostile environment for pathogensand prevent or attenuate respiratory infections. Both in vitro and in vivo experiments have been completed to validate this technology and the drug is progressing through the regulatory process for a treatment to benefit cancer patients during periods ofimmunocompromise. The focus of this proposal is to accomplish key milestones that will further transition this technology for commercialization for the asthma market by showing the direct benefit of PUL-042 in mouse asthma models. The project is organizedinto three measurable Specific Aims that include evaluating the safety and efficacy of PUL-042 in a mouse models of asthma. PUBLIC HEALTH RELEVANCE: Pulmotect, Inc is developing novel therapeutics that stimulate the innate immune system to protect against infectious diseases, even in cases of severely compromised immunity. Proof-of-concept data has shown that this technology effectively protects against a broad range of inhaled pathogens. This project will provide significant data to help transition this technology from the lab to the clinic for asthmatics. This work will leverage ongoing activities in developing the technology for cancer patients.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government